UK court allows CMA to amend Pfizer/Flynn appeal

A UK appeal court has granted permission for the Competition and Markets Authority to amend its grounds of appeal in the Pfizer/Flynn excessive pricing case, saying the United Brands test needs to be addressed.

Get unlimited access to all Global Competition Review content